Clinical trials: Vaccine Prophylaxis
Chronic Kidney Disease
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
The purpose of this study is to determine the durability of seroprotection of HEPLISAV™ and Engerix-B® and the number of injections of each vaccine needed to maintain seroprotection in a cohort of chronic kidney disease (CKD)…
- Trial name
- NCT01282762
- Testing
- HEPLISAV, Engerix-B
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Dynavax Technologies Corporation
Pneumonic Plague, Preventive Therapy
Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V
The purpose of this study is to evaluate the safety and tolerability of a two-dose schedule of the recombinant plague vaccine rF1V in healthy volunteers when given as an intramuscular (IM) injection at four ascending dose-levels.
- Trial name
- NCT00097396
- Testing
- rF1V vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Measles, Rubella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Measles, Rubella, Mumps, Varicella
- Trial name
- NCT00127010
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 48 sites in Belgium, Germany and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Coronavirus Disease (COVID-19)
Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19
Phase III Placebo-controlled adaptive multi-centre randomized controlled trial Interventional (Clinical Trial). The study will include nine hundred healthcare workers in the isolation hospitals for COVID-19 cases; they will be…
- Trial name
- NCT04350931
- Testing
- intradermal injection of BCG Vaccine
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Ain Shams University
COVID-19
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult…
- Trial name
- NCT06068569
- Testing
- GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza
Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40…
- Trial name
- NCT02015494
- Testing
- VAX2012Q
- Where
- 4 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Respiratory Syncytial Virus Infection, Healthy Volunteers
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial…
- Conditions
- Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
- Trial name
- NCT06237296
- Testing
- RSV/hMPV mRNA LNP 1, RSV/hMPV mRNA LNP 2, RSV mRNA LNP 1
- Where
- 17 sites in United States, Australia
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Infection
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
- Trial name
- NCT00310635
- Testing
- Meningococcal C conjugate vaccine
- Where
- Germany
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Novartis
BCG, COVID-19
Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers
In Mexico the total number of confirmed cases of COVID-19 is 232, 000 and 28,510 deaths. Health workers are at high risk of COVID-19 infection. Their absence from work dramatically limits the ability to contain the disease.
- Conditions
- BCG, COVID-19, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04461379
- Testing
- BCG vaccine
- Where
- Mexico
- Volunteers
- 908 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Flu
Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults
This is a Phase 1, randomized, double-blind, active- and placebo-controlled, multicenter, dose-ranging study to evaluate the safety, tolerability and Immunogenicity of a single non-adjuvanted dose of the H1 VLP Influenza vaccine…
- Trial name
- NCT01302990
- Testing
- Dose given at Day 0
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medicago
End Stage Renal Disease
Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
The purpose of this study is to compare the immune response to HEPLISAV™ booster injection with the immune response to Engerix-B® and Fendrix® booster vaccinations among patients with end stage renal disease (ESRD) on…
- Trial name
- NCT01195246
- Testing
- HEPLISAV, Engerix-B, Fendrix
- Where
- 19 sites in Germany
- Volunteers
- 155 people
- Sponsor
- Dynavax Technologies Corporation
Ductal Carcinoma in Situ
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
Women with biopsy-proven ductal carcinoma in situ (DCIS) will be enrolled into two cohorts. One cohort will receive neoadjuvant therapy with an aromatase inhibitor or selective estrogen receptor modulator (SERM) for about 12…
- Trial name
- NCT06218303
- Testing
- MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Finn, Olivera, PhD
Varicella
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age
This study assesses non-inferiority by comparing seroconversion rate of NBP608 to Varivax which are indicated for active immunization for prevention of varicella.
- Trial name
- NCT03114943
- Testing
- NBP608, Varivax
- Where
- Philippines
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
RSV Immunization
Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.
RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months.
- Trial name
- PIPELINE-RSV (NCT07041190)
- Testing
- Abrysvo, Nirsevimab
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- PENTA Foundation
Meningococcal Disease
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
This study is aimed to evaluate safety, tolerability and immunogenicity of three doses of Novartis 4CMenB and of one dose of Novartis Meningococcal ACWY vaccine when administered to healthy at-risk adults.
- Trial name
- NCT00560313
- Testing
- Men ACWY CRM, 4CMenB
- Where
- Italy
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine
The purpose of the study is to verify the safety and immunogenicity of a trivalent seasonal influenza vaccine with strain composition according to World Health Organization (WHO)/European Union (EU) recommendation for the…
- Trial name
- NCT01063088
- Testing
- Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)
- Where
- 2 sites in Austria, Belgium
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Cervix, Dysplasia, HPV Infection
Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
A retrospective cohort study of women treated by excisional therapy due to HSIL/ CIN at Clínico San Carlos Hospital between 2012-2018.
- Conditions
- Cervix, Dysplasia, HPV Infection, HPV Vaccine, Cervix Lesion
- Trial name
- VENUS (NCT04171505)
- Testing
- HPV vaccine
- Where
- Spain
- Volunteers
- 508 people
- Sponsor
- Hospital San Carlos, Madrid
Haemophilus Influenzae Type B Infection
Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children
This is a multicenter, post marketing surveillance study which aims to evaluate the safety profile of haemophilus influenza type b vaccine when administered to Korean children according to the product insert.
- Trial name
- NCT01404962
- Testing
- Haemophilus influenza type b conjugate vaccine
- Where
- 5 sites in South Korea
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Cardiovascular Disease, Dementia
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults.
- Trial name
- DAN-ZOSTER (NCT07485283)
- Testing
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Where
- 2 sites in Denmark
- Volunteers
- 168,460 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Influenza
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
The present study aims to evaluate the safety and immunogenicity of the new influenza subunit vaccine produced in Madin Darby Canine Kidney (MDCK) cells in healthy adult and elderly subjects.
- Trial name
- NCT00492063
- Testing
- Cell culture-derived trivalent subunit influenza vaccine (cTIV), Egg-derived trivalent subunit influenza vaccine (TIV)
- Where
- 5 sites in Poland
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines